CareDx, Inc. is dedicated to discovering, developing, and commercializing diagnostic solutions tailored for transplant patients and their caregivers globally. The company operates several innovative products, such as AlloSure Kidney, which utilizes donor-derived cell-free DNA (dd-cfDNA) for kidney transplant patients, and AlloMap Heart, a gene expression solution for heart transplant recipients. Additionally, it provides AlloSure Heart and AlloSure Lung, both dd-cfDNA solutions for heart and lung transplant patients, respectively. CareDx also introduces TruSight HLA, which is a next generation sequencing (NGS) based high-resolution typing solution, alongside Olerup SSP for typing human leukocyte antigen (HLA) alleles through sequence-specific primer technology. Other offerings include QTYPE for precise HLA typing, Ottr for transplant patient management, AlloSeq Tx for high-resolution HLA typing, AlloSeq cfDNA for blood surveillance of dd-cfDNA, AlloSeq HCT for chimerism testing in stem cell transplant recipients, and XynQAPI for transplant quality tracking. The company also offers AlloCare, a mobile app aimed at providing patient-centric resources for transplant recipients. CareDx markets its products directly to customers and utilizes third-party distributors and sub-distributors. The company has secured a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products, and with Cibiltech SAS to commercialize iBox, a predictive analysis software for post-transplantation kidney allograft loss. The company incurred an income tax expense of $271,000.00 indicating its tax obligations. It recorded a notable revenue of $379,805,000.00 showcasing its steady growth. Additionally, CareDx reported depreciation and amortization expenses of $20,416,000.00 reflecting the wear and tear of its assets, while the net total of other income and expenses is -$67,000.00 reflecting non-core financial activities. Finally, the company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The stock of CareDx is affordable at $14.59 making it a suitable option for budget-conscious investors. The stock has an average trading volume of 669,483.00 indicating moderate liquidity, which could attract interest from various investors. With a market capitalization of $863,039,733.00 the company is classified as a small-cap player, offering unique investment opportunities within the market. CareDx is recognized as a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative products and solutions. Furthermore, it belongs to the Healthcare sector, where it drives innovation and growth, establishing its pivotal role in the advancement of transplant diagnostics and patient care.